Bigbear Pharmaceutical·Medication Guide

• What if I miss a dose?

  Take the medication as soon as you remember. However, skip the missed dose if your next scheduled dose is in less than 12 hours. Do not take a double ···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 128

• Side Effects and Adverse Reactions of Cabozantinib

  Cabozantinib is a broad-spectrum anticancer drug with multiple targets, inhibiting at least nine targets including MET, VEGFR1/2/3, ROS1, RET, AXL, NT···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 121

• Cabozantinib Dosage and Administration: Common Dosage and Dosage Adjustment

  Cabozantinib is a small-molecule, multi-target tyrosine kinase inhibitor developed by Exelixis in the United States. In November 2012, the FDA first a···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 119

• FDA Approves Cabozantinib (Cabometyx) for Previously Treated Patients with Advanced Neuroendocrine T

  On March 26, 2025, Exelixis announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of two ···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 104

• Detailed instructions for Cabozantinib: indications, dosage, side effects, and precautions

  Cabozantinib is a broad-spectrum, multi-target anti-tumor drug developed by Exelixis Biopharmaceuticals, Inc. While most anti-tumor drugs target 1-3 t···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 118

• Cabozantinib (Cabometyx) instruction manual

  Cabozantinib (Cabometyx), first approved by the FDA in 2012, is a non-specific tyrosine kinase inhibitor. It exerts its anti-tumor effect by targeting···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 109

• The FDA has approved lorlatinib for the treatment of previously treated ALK-positive metastatic non

  On November 2, 2018, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved lorlatinib, a third-generation anaplastic lymphoma···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 114

• The FDA has expanded the indications for lorlatinib, approving it for first-line treatment of ALK-po

  On March 3, 2021, the U.S. Food and Drug Administration (FDA) approved Pfizer's supplemental New Drug Application (sNDA) for lorlatinib, expanding···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 116

• Detailed product information for Lorlatinib: indications, dosage, side effects, and precautions

  Lorlatinib, the world's first third-generation ALK (anaplastic lymphoma kinase)/ROS1 tyrosine kinase inhibitor (TKI), was developed by Pfizer for ···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 114

• Lorlatinib Explained: Uses, Mechanism of Action, and Clinical Outcomes

  Lorlatinib was approved for marketing in China by the National Medical Products Administration (NMPA) in April 2022 and has been included in the Natio···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 137

• Managing Lorlatinib Side Effects: A Guide to Common Symptoms and How to Cope

  Lorlatinib is a novel third-generation small-molecule ALK/ROS1 dual-target inhibitor developed by Pfizer Inc.Side effects requiring immediate medical ···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 113

• Lorlatinib Dosage Guide: What is the Recommended Starting Dose for ALK-Positive Lung Cancer?

  Lorlatinib was first approved for marketing in Japan in September 2018, followed by approval from the U.S. Food and Drug Administration (FDA) in Novem···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 106

• FDA approves cannefenib in combination with bimetinib

  On October 12, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved cannefenib in combination with bimetinib for the t···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 117

• Binimetinib (Mektovi) Uses, Dosage, Side Effects & Patient Tips

  In June 2018, the U.S. Food and Drug Administration (FDA) approved binimetinib for marketing as a treatment for unresectable metastatic melanoma or me···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 122

• What is lusutrombopag

  Lusutrombopag is a man-made form of a protein that increases production of platelets (blood-clotting cells) in your body. Lusutrombopag can lower the ···【Read More】

  Update: 2026-03-05Source: Haiou HealthViews: 115